Answer
Somatrogon must not be used when there is any evidence of tumour activity; intracranial tumours must be inactive and antitumour therapy completed before starting growth hormone therapy, and treatment should stop if tumour growth occurs.
Sources for this answer
- Ngenla 60 mg solution for injection in pre-filled penPfizer Limited · emc · SmPC §4.3 Contraindications · Version 7Document updated
Sources checked